Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) PT at $14.60

Shares of NeuroPace, Inc. (NASDAQ:NPCE) have been given an average recommendation of “Moderate Buy” by the six analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $14.60.

A number of research firms have issued reports on NPCE. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price target on shares of NeuroPace in a report on Wednesday, August 14th. Wells Fargo & Company reduced their target price on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Wednesday, November 13th.

Insider Activity

In other NeuroPace news, major shareholder Ltd. Kck sold 4,031 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $6.54, for a total transaction of $26,362.74. Following the completion of the transaction, the insider now owns 5,521,874 shares in the company, valued at $36,113,055.96. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have sold 257,590 shares of company stock valued at $1,437,916. Company insiders own 22.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of NeuroPace by 18.3% in the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock valued at $6,450,000 after buying an additional 75,512 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of NeuroPace in the 2nd quarter valued at $257,000. Financial Advocates Investment Management boosted its holdings in shares of NeuroPace by 50.0% in the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after buying an additional 5,000 shares in the last quarter. Rhumbline Advisers acquired a new position in shares of NeuroPace in the 2nd quarter valued at $111,000. Finally, Acadian Asset Management LLC boosted its holdings in shares of NeuroPace by 46.0% in the 2nd quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after buying an additional 21,703 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace Price Performance

NASDAQ NPCE opened at $10.25 on Monday. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. The firm’s 50 day moving average price is $7.27 and its 200-day moving average price is $7.28. NeuroPace has a 52-week low of $5.45 and a 52-week high of $18.15. The company has a market cap of $305.96 million, a PE ratio of -10.32 and a beta of 1.79.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.07. The company had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same period last year, the firm earned ($0.28) earnings per share. Sell-side analysts forecast that NeuroPace will post -1 EPS for the current fiscal year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.